1-5 of 5
Alex Uttard
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios

Susan M. Clardy, Alex Uttard, Bingfan Du, Kalli C. Catcott, Kelly L. Lancaster, Elizabeth Ditty, Jack Sadowsky, Jeffrey Zurita, Naniye Malli, LiuLiang Qin, Stephen P. Bradley, Kenneth Avocetien, Tyler Carter, Dokyong Kim, Mark Nazzaro, Ling Xu, Thomas H. Pillow, Neelie T. Zacharias, Gail D. Lewis, Rebecca K. Rowntree, Radha Iyengar, David H. Lee, Marc Damelin, Dorin Toader, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (1): 84–91.
https://doi.org/10.1158/1535-7163.MCT-23-0262
Published: 03 January 2024
View article titled, Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Open the PDF for Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios in another window
Includes: Supplementary data
Journal Articles

Abstract P167: Site-specific Dolasynthen ADCs demonstrate consistent exposure across a wide range of drug-to-antibody ratios

Kalli C. Catcott, Susan Clardy, Jack Sadowsky, Rebecca K. Rowntree, Naniye Malli Centibas, Ling Xu, Andy Polson, Kenneth Avocetien, Tyler Carter, Mark Nazzaro, Dokyong "DK" Kim, Thomas H. Pillow, Neelie Zacharias, Cong Wu, Jeffrey Zurita, Elizabeth Ditty, Stephen Bradley, Alex Uttard, Bingfan Du, William S. Sawyer, Doug Leipold, Gail Lewis Phillips, LiuLiang Qin, Kelly Slocum, Geoffrey Del Rosario, Ginny Li, Shang-Fan Yu, David Lee, Radha Iyengar, Marc Damelin, Dorin Toader, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P167.
https://doi.org/10.1158/1535-7163.TARG-21-P167
Published: 01 December 2021
View article titled, Abstract P167: Site-specific Dolasynthen ADCs demonstrate consistent exposure across a wide range of drug-to-antibody ratios
Journal Articles

Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect

Aleksandr V. Yurkovetskiy, Natalya D. Bodyak, Mao Yin, Joshua D. Thomas, Susan M. Clardy, Patrick R. Conlon, Cheri A. Stevenson, Alex Uttard, LiuLiang Qin, Dmitry R. Gumerov, Elena Ter-Ovanesyan, Charlie Bu, Alex J. Johnson, Venu R. Gurijala, Dennis McGillicuddy, Michael J. DeVit, Laura L. Poling, Marina Protopopova, Ling Xu, Qingxiu Zhang, Peter U. Park, Donald A. Bergstrom, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (5): 885–895.
https://doi.org/10.1158/1535-7163.MCT-20-0166
Published: 01 May 2021
View article titled, Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect
Open the PDF for Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect in another window
Includes: Supplementary data
Journal Articles

The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b

Natalya D. Bodyak, Rebecca Mosher, Aleksandr V. Yurkovetskiy, Mao Yin, Charlie Bu, Patrick R. Conlon, Damon R. Demady, Michael J. DeVit, Dmitry R. Gumerov, Venu R. Gurijala, Winnie Lee, Dennis McGillicuddy, Peter U. Park, Laura L. Poling, Marina Protopova, LiuLiang Qin, Cheri A. Stevenson, Elena Ter-Ovanesyan, Alex Uttard, Dongmei Xiao, Jian Xu, Ling Xu, Donald A. Bergstrom, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (5): 896–905.
https://doi.org/10.1158/1535-7163.MCT-20-0183
Published: 01 May 2021
View article titled, The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b
Open the PDF for The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b in another window
Includes: Supplementary data
Journal Articles

Abstract C238: Polyacetal polymer-based anti-HER2 antibody-drug conjugate employing cysteine bioconjugation through thioether linkage allows a high drug loading of dolastatin-derived payload with excellent pharmacokinetics and potent anti-tumor activity.

Joshua Thomas, Alex Yurkovetskiy, Natalya Bodyak, Mao Yin, Patrick Conlon, Cheri Stevenson, Alex Uttard, Liu Qin, Dmitry Gumerov, Elena Ter-Ovaneysan, Michael DeVit, Laura L. Poling, Peter U. Park, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C238.
https://doi.org/10.1158/1535-7163.TARG-13-C238
Published: 01 November 2013
View article titled, Abstract C238: Polyacetal polymer-based anti-HER2 antibody-drug conjugate employing cysteine bioconjugation through thioether linkage allows a high drug loading of dolastatin-derived payload with excellent pharmacokinetics and potent anti-tumor activity.